T1	HMM 329 379	accelerated development of cardiovascular disease.
T2	HMM 543 558	LDL cholesterol
T3	HMM 1632 1677	change in ultracentrifugation LDL cholesterol
T4	HMM 2078 2121	reduced ultracentrifugation LDL cholesterol
T5	HMM 2172 2183	p<0Â·0001).
T6	HMM 2184 2210	Treatment-emergent adverse
T7	HMM 2379 2422	and no anti-evolocumab antibody development
T8	HMM 2648 2666	was well tolerated
T9	HMM 2685 2708	reduced LDL cholesterol
